SuspendedNot Applicable

Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy

Stopped: on hold for analysis

United States500 participantsStarted 2023-05-30

Plain-language summary

This study evaluates genetic testing to improve risk assessment and advance efforts to develop precision management for breast cancer by studying saliva samples for genotyping and evaluate associations with pathologic diagnoses and detailed pathologic and radiologic features.

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * \* Women over the age of 18 years * Able to provide informed consent * Referred for a radiologically guided breast biopsy Exclusion Criteria: * \* Men * Women under the age of 18 years * Unable to provide informed consent

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of subjects consented per month

Timeframe: Baseline; Up to study completion (approximately 5 years)

Deoxyribonucleic acid (DNA) quantity

Timeframe: Up to study completion (approximately 5 years)

Deoxyribonucleic acid (DNA) quality

Timeframe: Up to study completion (approximately 5 years)

Ability to perform genotyping using collected sample

Timeframe: Up to study completion (approximately 5 years)

Success in estimation of polygenic risk score (PRS)

Timeframe: Up to study completion (approximately 5 years)

Trial details

NCT IDNCT06060561

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-06-30

View on ClinicalTrials.gov More Breast Carcinoma trials

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of subjects consented per month

Timeframe: Baseline; Up to study completion (approximately 5 years)

Deoxyribonucleic acid (DNA) quantity

Timeframe: Up to study completion (approximately 5 years)

Deoxyribonucleic acid (DNA) quality

Timeframe: Up to study completion (approximately 5 years)

Ability to perform genotyping using collected sample

Timeframe: Up to study completion (approximately 5 years)

Success in estimation of polygenic risk score (PRS)

Timeframe: Up to study completion (approximately 5 years)